Results from a Phase 2 Study of Triplet Blockade of the IL-27, PD-(L)1, and VEGF Pathways with Casdozokitug (casdozo, CHS-388) in Combination with Atezolizumab and Bevacizumab in Patients with Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma (Uhcc).
Journal of Clinical Oncology（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined